AccelPharma plans to build a sterile injectable drug manufacturing facility within a US Federally approved Opportunity Zone in the SouthEast.

The AccelPharma team combines decades of experience, operating history, and specific knowledge in pharma production. The team recently completed an operational sterile oncology drugs manufacturing facility in Mudanjiang, China.

In recent years the developments in cutting edhge modular construction technologies speed up the buildout process in compliance with jurisdictional certification requirements. AccelPharma will utilize the latest developments in modular construction for faster buildout and quicker certification of the facility.

Apart from oncology drugs manufacturing, the project can contribute to vaccine production, including COVID-19 vaccine.

The negotiated terms within the Opportunity Zone provide substantial tax deferral and capital return advantages to project investors.

Oasmia Pharmaceutical AB (publ) develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. It focuses on manufacturing formulations based on cytostatics. The company offers Apealea /Paclical for the treatment of ovarian cancer that has completed phase III clinical trial, as well as in phase I clinical trial for the treatment of metastatic breast cancer. It also provides Doxophos for the treatment of various doxorubicin indications; Docecal, which is in phase II clinical trial for the treatment of breast cancer; and OAS-19 and KB9520, which are in pre-clinical stage for the treatment of various cancers. In addition, the company’s animal health product portfolio includes Paccal Vet to treat mastocytoma that has completed phase I clinical trial and conducts phase II clinical trial for the treatment of mammary carcinoma and squamous cell carcinoma; and Doxophos Vet, which is in phase II clinical trial to treat lymphoma. Oasmia Pharmaceutical AB was founded in 1988 and is headquartered in Uppsala, Sweden.

Simcere Pharmaceutical Group engages in the research, development, manufacture, and distribution of pharmaceutical and vaccine products for pharmaceutical distributors and government in China. Its principal branded generic pharmaceuticals include Bicun, a prescription edaravone injection pharmaceutical for the treatment of strokes; Zailin, a line of generic prescription amoxicillin antibiotics; Yingtaiqing, an anti-inflammatory pain reliever and analgesic drug used to treat rheumatoid arthritis and osteoarthritis; Yidasheng, a prescription edaravone injection pharmaceutical for the treatment of strokes; and Sinofuan for the treatment of cancer. The company also offers generic anti-diarrhea pharmaceutical products under the Biqi brand; amoxicillin and clavulanate potassium tablets, granules, and injection for the treatment of infections under the Anqi brand name; cefaclor in dry suspension antibiotics for the treatment of infections under the Zaike brand; herbal medicines for the treatment of coughs under the Simcere Kechuanning name

G-CON is the global leader of cleanroom design and construction with a POD portfolio that encompasses a variety of different dimensions and purposes, from aseptic fill/finish and laboratory environments to advanced therapies and production process platforms.

Dr. Spear serves on our technical advisory board and joined the team in 2Q2020. He currently serves as chief medical officer of Poseida Therapeutics, a clinical-stage biopharmaceutical company leveraging proprietary next-generation, non-viral gene engineering technologies to create life-saving cell therapeutics for patients with high unmet medical need. Previously, Dr. Spear served as head of clinical development and vice president at Sangamo Biosciences Inc., and as vice president, clinical development and translational medicine at Incyte Corporation, a research company specializing in oncology product development and innovative medicines.

Dr. Spear served as head of oncology and head of biotherapeutics at Sunovion Pharmaceuticals, Inc. and held several roles at Nereus Pharmaceuticals, Inc., including chief medical officer. Dr. Spear has led multiple oncology clinical development programs at Pfizer as an associate professor at the Keck School of Medicine of USC, and the UCSD School of Medicine and UCSD Cancer Center. He has also served on NIH/NCI study section, biotechnology and pharmaceutical advisory boards, IRB/SRC and scientific journal editorial review committees related to cancer, as well as authoring numerous scientific papers and patents. Dr. Spear completed his residency and fellowship at the Massachusetts General Hospital/Harvard University program. Dr. Spear received his M.D. from Stanford University Medical School and his B.S. and B.A. in biology from Johns Hopkins University.

Major Comstock is a Vietnam veteran whose awards include the Defense Superior Service Medal, Legion of Merit and the Bronze Star with “V”. He is a member of the Michigan State University Army ROTC Hall of Fame. In addition, he has over 40 years of experience in the insurance, investment and business consulting professions. Jim is the CEO of Optical Technologies Inc and is a Co-founder & Principal of Veracor Group, LLC.

Colin Breeze is a co-founder of Alpha Capital, LLC. He brings deep transactional and capital formation experience. Before forming Alpha, Colin worked with serial entrepreneurs in the blockchain space as principal and advisor and led multiple digital securities projects. In addition, Colin has practiced corporate and securities law since 1998, advising private and public companies and private equity funds in all aspects of their organization: capital raising, reporting, investor relations, transactions, intellectual property protection, governance and transparency. He also has deep experience in fin-tech projects, having advised or participated in dozens of blockchain and tokenization projects.

Colin specializes in all areas of corporate, securities and partnership transactions, including the formation and financing of companies, public offerings, debt transactions, corporate governance and investor-side financings. Colin’s experience spans the entire business lifecycle, including strategic decisions and coaching prior to company or fund formation, business development, growth stage financing, initial public offerings and mergers and acquisitions. In particular, Colin’s experience in fund formation and management includes the structuring, organization and operation of venture capital and private equity funds and their general partners and related management company entities. Colin advises funds on all aspects of their operations, including the preparation of offering materials, the fundraising process, negotiations with investors, and investments and divestments from the portfolio.

John has been an adjunct professor of business for Central Texas College since 2005. He is the founding principal and managing partner of Fiduciary Solutions Financial Services, Inc. and Fiduciary Solutions Insurance Agency, LLC in Atlanta for over 15 years. John is a co-founder and partner of Veracor Group, and previously served as vice president of Medical Association of Georgia Mutual Financial Services, serving the needs of over 17,000 owner-insured physicians in Georgia and the contiguous states.

Roman has over 15 years of mission critical project development, supervision, and executive management experience, primarily in the pharma/biopharma industry. Roman possesses a strong background in strategic project analysis, design review, pre-construction, contractor selection, procurement, and site management. He is highly knowledgeable at scheduling, budget development and monitoring, contract negotiations, and work force relationship management. Projects Roman has worked on include greenfield and renovations, pilot labs, aseptic filling suites, lyophilization additions, and large-scale bio process facilities.

Roman’s experience spans both human and animal pharmaceutical projects for small startups and global companies. His previous success is built on strong interpersonal skills, attentiveness to details, and a drive for continuous improvement.

Mark Taylor has 12 years of experience in R&D, innovative product improvement, and intricate fabrication projects. For four years he has been instrumental in the continued improvement of G-CON PODs and the structured methodology in which they are produced. His diverse background includes project management for the automotive manufacturing industry, design and manufacture of personal protective equipment and sensors, and design and execution of proprietary welding processes and equipment as well as assembly of pressure level equipment for pharmaceutical and petroleum industries.

Mark has extensive lean manufacturing training and comprehensive experience in general construction, welding, rapid prototyping, injection molding, machining, and 3-D modeling. He has driven the effort to improve quality systems throughout his career, including but not limited to ISO 9001 and ISO 3834. Mark received his B.S in Mechanical Engineering from the University of Pittsburgh with a Minor in Material Science. In addition, Mark provided four years of meritorious service in the United States Marine Corps. During this time, he rose to the level of Sergeant and led troops in both Operation Enduring Freedom and Operation Iraqi Freedom.

ONGX tokens are listed and tradable on the Hobit.io Digital Assets Exchange. Visit coin sàn gate io for more information. Register on Hobit.io to receive 100 HOBT coins after you buy ONGX Equity tokens.